Although emerging therapeutics such as SGLT2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, factors such as the potential risk of genitourinary tract infections with SGLT2 inhibitors, their restricted use in DKD patients with significantly reduced glomerular filtration rates, and gastrointestinal tolerability issues with GLP-1 receptor agonists that may hinder long-term adherence, collectively underscore the need for additional strategies to improve the prognosis and quality of life of DKD patients [21,22]. This evidence concerns the gene GLP1R and diabetic kidney disease.